Anthony G. Quinn Buys 125,791 Shares of Generation Bio Co. (NASDAQ:GBIO) Stock

Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn acquired 125,791 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were bought at an average cost of $0.96 per share, for a total transaction of $120,759.36. Following the acquisition, the director now owns 214,286 shares of the company’s stock, valued at $205,714.56. This represents a 142.14 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Generation Bio Trading Up 6.6 %

Shares of GBIO opened at $0.95 on Friday. The company has a 50-day moving average of $1.30 and a two-hundred day moving average of $2.11. The stock has a market cap of $63.20 million, a P/E ratio of -0.43 and a beta of 2.72. Generation Bio Co. has a 12-month low of $0.75 and a 12-month high of $4.65.

Analysts Set New Price Targets

Several brokerages have recently commented on GBIO. Wedbush reissued an “outperform” rating and set a $5.00 price target on shares of Generation Bio in a research note on Thursday, November 7th. Needham & Company LLC lowered their target price on Generation Bio from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th.

Institutional Investors Weigh In On Generation Bio

Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC increased its position in Generation Bio by 0.3% during the third quarter. FMR LLC now owns 5,320,266 shares of the company’s stock worth $13,141,000 after buying an additional 15,656 shares in the last quarter. Baker BROS. Advisors LP boosted its stake in shares of Generation Bio by 61.1% during the third quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock valued at $4,804,000 after acquiring an additional 737,988 shares during the last quarter. State Street Corp boosted its stake in shares of Generation Bio by 1.2% during the third quarter. State Street Corp now owns 992,188 shares of the company’s stock valued at $2,451,000 after acquiring an additional 11,669 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Generation Bio by 2.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock worth $1,046,000 after purchasing an additional 8,692 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Generation Bio by 31.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company’s stock valued at $527,000 after purchasing an additional 44,378 shares during the last quarter. Hedge funds and other institutional investors own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.